A similar multicenter cohort of R/R lymphoma, including DLBCL patients, showed that wide-spectrum antibiotics exposure (‘high-risk antibiotics’) prior to CD19-targeted CART therapy is associated with adverse outcomes, but this effect is likely to be confounded by an increased pre-treatment tumor burden and systemic inflammation in patients [400]. The gene discussed is CD19; the disease is neoplasm.